Kathrin Thedieck, Ph.D.

Kathrin Thedieck, Ph.D.

Univ.-Prof. Dr.rer.nat.

Institute of Biochemistry
University of Innsbruck
Room no. L.03.012


Center for Chemistry and Biomedicine (CCB) Innrain 80-82, 6020 Innsbruck / Austria
Phone: +43 512 507 - 57500 | Fax: +43 512 507 - 57599
Email: kathrin.thedieck@uibk.ac.at

  Lab for Metabolic Signaling

Research Interest

The Lab for Metabolic Signaling studies the control of metabolic homeostasis by kinase networks centred on the mammalian target of rapamycin (mTOR). We adopt biochemistry, cell biology, proteomics, metabolomics and systems modelling approaches.

mTOR is a central controller of metabolism and ageing. mTOR is dysregulated in most cancers as well as in metabolic, neurodegenerative and congenital disorders, and is therefore of major biomedical interest as a drug target and biomarker. The kinase mTOR is at the center of a complex signaling and metabolic network, and exists in two structurally and functionally distinct multiprotein complexes, mTOR complex 1 (mTORC1) and mTORC2. In response to growth factors, nutrients, energy  and stress, mTORC1 enhances anabolic processes such as translation, and represses catabolic processes such as autophagy. mTORC2 is a central metabolic regulator as well which is involved in lipid and glucose homeostasis.

mTOR controls virtually all metabolic processes at the cellular and organismal level. But how are specific metabolic responses to distinct metabolic inputs achieved? We hypothesize that different molecular networks transduce specific metabolic stimuli and mTOR-dependent metabolic responses. Hence, we aim to identify novel mTOR network components and delineate their interconnection in relation to different metabolic inputs and outputs. To this end, our lab analyzes the mTOR interactome and phosphotargets using proteomic and biochemical methods (Schwarz et al. 2015). To deal with mTOR network complexity, systems approaches are adopted to unravel novel regulatory connections governing mTOR’s activity and outputs (Dalle Pezze 2016Sonntag et al 2012Dalle Pezze 2012). We functionally characterize novel mTOR regulators by means of biochemistry, cell biology and in vivo. For example, we investigate regulators which control mTOR activity and cellular survival under stress (Heberle & Razquin-Navas et al. 2019; Heberle et al. 2015Thedieck et al. 2013), and we unravel mTOR crosstalk with other signaling networks such as TGFbeta (Thien et al. 2015) and autophagy (Ruf et al. 2017).

 

Funding

02/21 – 01/23 H2020 SwafS-08-2019-2020 VERSA – Video gamEs foR Skills training.
Project number 101006420
09/19 – 08/23 H2020-MSCA-COFUND-2018 ARDRE – Ageing, Regeneration, and Drug Re-search*
K. Thedieck is co-coordinator.
Marie Skłodowska-Curie grant agreement No 847681
10/18 – 09/22 H2020 ITN PoLiMeR – Polimers in the Liver – Metabolism and Regulation
K. Thedieck is WP leader.
Marie Skłodowska-Curie grant agreement No 812616
01/20 – 06/22 Deutsche TS Stiftung e.V. – Metabolic profiling of TS patients with epilepsy
K. Thedieck is coordinator.
01/18 – 09/22 H2020 SC1-PM-02-2017 MESI-STRAT Systems Medicine of Metabolic-Signaling networks: A New Concept for Breast Cancer Patient Stratification
K. Thedieck is coordinator.
Grant agreement No 754688
01/18 – 06/21 Oldenburg-Groningen Joint Graduate Research Training Group
K. Thedieck is co-speaker of the graduate college.
PhD project
10/17 – 12/20 Stichting TSC Fonds – Exploring Metabolic Changes with Potential Treatment Implications in TSC Patients: A Multicenter Pilot Study
Collaborative project with D. Mekahli, MD, PhD, University Hospital Leuven, BE
10/16 – 09/19 German Research Council (DFG) – Development of a miniaturized analysis plat-form for quantitative time-resolved high throughput analysis of Akt-mTOR sig-naling network kinetics in cancer cells
Project number TH 1358/3-1
01/16 – 12/17 Ubbo Emmius Funds – Individualized tumor therapy for children with tuberous sclerosis complex (TSC) disease.

 


Nach oben scrollen